Ani Pharmaceuticals (ANIP) Common Equity (2010 - 2026)

Ani Pharmaceuticals has disclosed Common Equity across 17 years of filings, most recently posting $597.2 million for Q2 2026.

• In Q2 2026, Common Equity rose 36.74% year-over-year to $597.2 million; the TTM figure through Jun 2026 stood at $597.2 million (up 36.74% YoY), while the FY2025 annual figure was $540.7 million, up 33.95% from the prior year.
• Common Equity came in at $597.2 million for Q2 2026 at Ani Pharmaceuticals, up from $562.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $597.2 million in Q2 2026 to a low of $311.8 million in Q3 2022.
• Average Common Equity over 5 years is $423.6 million, with a median of $424.2 million recorded in 2023.
• Year-over-year, Common Equity soared 62.92% in 2022 and decreased 7.38% in 2025.
• Over 5 years, Common Equity stood at $313.7 million in 2022, then jumped by 37.95% to $432.7 million in 2023, then fell by 6.72% to $403.7 million in 2024, then surged by 33.95% to $540.7 million in 2025, then grew by 10.45% to $597.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $597.2 million in Q2 2026, $562.3 million in Q1 2026, and $540.7 million in Q4 2025.